West Pharmaceutical Services (WST) Tops Q4 Earnings and Revenue Estimates

Core Insights - West Pharmaceutical Services (WST) reported quarterly earnings of $2.04 per share, exceeding the Zacks Consensus Estimate of $1.83 per share, and showing an increase from $1.82 per share a year ago, resulting in an earnings surprise of +11.21% [1] - The company achieved revenues of $805 million for the quarter ended December 2025, surpassing the Zacks Consensus Estimate by 1.35% and increasing from $748.8 million year-over-year [2] - West Pharmaceutical has consistently surpassed consensus EPS estimates over the last four quarters, indicating strong performance [2] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is $1.64, with expected revenues of $759.74 million, while for the current fiscal year, the EPS estimate is $7.67 on revenues of $3.24 billion [7] - The company's favorable estimate revisions trend prior to the earnings release has resulted in a Zacks Rank 2 (Buy), suggesting expected outperformance in the near future [6] Industry Context - The Medical - Dental Supplies industry, to which West Pharmaceutical belongs, is currently ranked in the top 33% of over 250 Zacks industries, indicating a favorable outlook compared to lower-ranked industries [8] - Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5]